Dynamic FIB-4 Changes Track Fibrosis Progression and Predict Outcomes in MASLD
Changes in the Fibrosis-4 Index (FIB-4) over time are strongly associated with fibrosis progression, liver stiffness worsening, and adverse clinical outcomes in patients with metabolic dysfunction–associated steatotic liver disease (MASLD), according to a large, multicohort analysis.
Investigators analyzed data from three complementary cohorts encompassing more than 52,000 patients. The VCTE-Prognosis cohort evaluated liver stiffness progression, the Paired Liver Biopsy cohort assessed histologic fibrosis progression, and the Wenzhou Real-World cohort examined long-term clinical outcomes, including mortality, cardiovascular events, and liver-related events. FIB-4 was categorized as low (<1.3) or high (≥1.3), with dynamic increases defined by a ≥20% rise, with threshold crossing in the low FIB-4 group.
Across cohorts, increasing FIB-4 consistently identified patients at higher risk. In the VCTE-Prognosis cohort, patients with rising FIB-4 were significantly more likely to experience liver stiffness progression compared with those with stable FIB-4, regardless of baseline category. Similar patterns were observed in the biopsy cohort, where fibrosis progression was more frequent among patients with increasing FIB-4 in both low and high baseline groups.
Clinical relevance was reinforced in the real-world cohort. Patients with increasing dynamic FIB-4 had significantly higher risks of all-cause mortality, cardiovascular events, and liver-related events. These associations remained robust after adjustment for confounders.
The authors concluded that “dynamic FIB-4 monitoring tracks fibrosis and stiffness progression and predicts clinical outcomes in MASLD,” underscoring its value as a longitudinal risk assessment tool. They further emphasized that changes in FIB-4, rather than static values alone, provide meaningful insight into disease trajectory.
Routine, serial assessment of FIB-4 may help identify patients with MASLD who are at risk for progression and adverse outcomes. Incorporating dynamic FIB-4 trends into clinical follow-up could support earlier intervention, closer monitoring, and more informed risk stratification in a growing population with metabolic liver disease.
Reference
Zhou XD, Li YT, Kim SU, et al. Longitudinal changes in fibrosis markers: monitoring stiffness/fibrosis progression and prognostic outcomes in MASLD. Clin Gastroenterol Hepatol. 2026;24(2):394-406. doi:10.1016/j.cgh.2025.07.011
